![](http://bsg-s.nbxc.com/site_themes/common/inquiry_popup/images/close.png)
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
새로운 구강 인자 XA 억제제 APXAB는 Bristol-Myers Squibb 및 Pfizer가 공동 개발 한 구강 인자 XA 억제제의 새로운 유형입니다. 그것의 상표명은 엘렐토입니다. 그것은 새로운 유형의 경구 항응고제입니다. 중요한 응고 인자 XA를 억제함으로써 APIXAB는 트롬빈 생성 및 혈전증을 방지 할 수 있습니다.
제품 디렉토리 : API 중간체 > Cas 503612-47-3용 중간체
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.
Fill in more information so that we can get in touch with you faster
Privacy statement: Your privacy is very important to Us. Our company promises not to disclose your personal information to any external company with out your explicit permission.